ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ABMD
  • CUSIP: 00365410
Key Metrics:
  • Previous Close: $114.25
  • 50 Day Moving Average: $110.97
  • 200 Day Moving Average: $116.57
  • 52-Week Range: $43,430,000.00 - $78.46
  • Trailing P/E Ratio: 108.94
  • Foreward P/E Ratio: 66.23
  • P/E Growth: 3.87
  • Market Cap: $5075.34B
  • Outstanding Shares: 43,430,000
  • Beta: 0.51
  • Net Margins: 11.63%
  • Return on Equity: 12.35%
  • Return on Assets: 10.54%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 5.66%
  • Quick Ratio: 5.12%
Additional Links:
Companies Related to ABIOMED:

Analyst Ratings

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $147.00 (26.10% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
DateFirmActionRatingPrice TargetDetails
1/8/2017BTIG ResearchReiterated RatingBuy$170.00View Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00View Rating Details
9/28/2016Leerink SwannReiterated RatingOutperform$125.00View Rating Details
8/9/2016Jefferies Group LLCBoost Price TargetBuy$130.00 -> $145.00View Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00View Rating Details
2/5/2016Piper Jaffray CompaniesReiterated RatingHold$75.00 -> $90.00View Rating Details
10/30/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$85.00View Rating Details
10/29/2015Sterne Agee CRTReiterated RatingBuyView Rating Details
8/17/2015CRT CapitalInitiated CoverageBuyView Rating Details
8/14/2015StephensReiterated RatingOverweight$103.00 -> $128.00View Rating Details
8/5/2015Northland SecuritiesBoost Price TargetMarket Perform$60.00 -> $80.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for ABIOMED (NASDAQ:ABMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/28/2015Q315$0.04$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.03$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.01($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.08$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ABIOMED (NASDAQ:ABMD)
Current Year EPS Consensus Estimate: $1.18 EPS
Next Year EPS Consensus Estimate: $1.76 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.12$0.20$0.16
Q2 20163$0.22$0.25$0.23
Q3 20164$0.19$0.28$0.25
Q4 20164$0.25$0.34$0.29
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.39$0.43$0.41
Q2 20183$0.29$0.37$0.33
Q3 20183$0.44$0.49$0.47
Q4 20183$0.47$0.54$0.50
Q1 20191$0.41$0.41$0.41
(Data provided by Zacks Investment Research)


Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ABIOMED (NASDAQ:ABMD)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 92.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ABIOMED (NASDAQ:ABMD)
capitalcube.com logoABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : ABMD-US : February 17, 2017 (NASDAQ:ABMD)
www.capitalcube.com - February 17 at 6:51 PM
nasdaq.com logoImplied IYH Analyst Target Price: $169 (NASDAQ:ABMD)
www.nasdaq.com - February 16 at 3:17 PM
capitalcube.com logoETFs with exposure to ABIOMED, Inc. : February 14, 2017 (NASDAQ:ABMD)
www.capitalcube.com - February 14 at 3:20 PM
finance.yahoo.com logoABIOMED INC Financials (NASDAQ:ABMD)
finance.yahoo.com - February 9 at 3:13 PM
News IconInvestor Focus: Watching Shares of ABIOMED, Inc. (NASDAQ:ABMD) - Baldwin Journal (NASDAQ:ABMD)
baldwinjournal.com - February 8 at 3:21 PM
biz.yahoo.com logoABIOMED INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ABMD)
biz.yahoo.com - February 8 at 3:21 PM
News IconWhy Analysts put forward these two stocks: CyrusOne Inc. (CONE), ABIOMED, Inc. (ABMD) - The USA Commerce (NASDAQ:ABMD)
theusacommerce.com - February 7 at 8:22 PM
seekingalpha.com logoAbiomed up 5% on Abbott's trevails with HeartMate (NASDAQ:ABMD)
seekingalpha.com - February 6 at 3:42 PM
capitalcube.com logoETFs with exposure to ABIOMED, Inc. : February 2, 2017 (NASDAQ:ABMD)
www.capitalcube.com - February 2 at 3:16 PM
News IconStock in Focus: ABIOMED, Inc. (NASDAQ:ABMD) - The Tribune (NASDAQ:ABMD)
lakecitytribune.com - January 30 at 8:28 PM
News IconAre Analysts Predicting a Near-Term Upswing For ABIOMED, Inc. (NASDAQ:ABMD)? - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 30 at 3:26 PM
nasdaq.com logoAbiomed (ABMD) Beats Earnings & Revenue Estimates in Q3 - Nasdaq (NASDAQ:ABMD)
www.nasdaq.com - January 30 at 3:26 PM
capitalcube.com logoABIOMED, Inc. :ABMD-US: Earnings Analysis: Q3, 2017 By the Numbers : January 30, 2017 (NASDAQ:ABMD)
www.capitalcube.com - January 30 at 3:26 PM
istreetwire.com logoStocks Under Consideration: Expeditors International of Washington, Inc. (EXPD), ABIOMED, Inc. (ABMD), BorgWarner ... - iStreetWire (NASDAQ:ABMD)
istreetwire.com - January 27 at 3:24 PM
News IconAbiomed INC (ABMD) Shareholder Cupps Capital Management LLC Has Trimmed Its Position by $9.75 Million as Stock Rose (NASDAQ:ABMD)
randolphguide.com - January 27 at 1:35 AM
us.rd.yahoo.com logoAbiomed Announces Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year (NASDAQ:ABMD)
us.rd.yahoo.com - January 27 at 1:35 AM
biz.yahoo.com logoQ3 2017 Abiomed Inc Earnings Release - Before Market Open (NASDAQ:ABMD)
us.rd.yahoo.com - January 27 at 1:35 AM
capitalcube.com logoABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : ABMD-US : January 26, 2017 (NASDAQ:ABMD)
us.rd.yahoo.com - January 27 at 1:35 AM
biz.yahoo.com logoAbiomed Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:ABMD)
us.rd.yahoo.com - January 27 at 1:35 AM
finance.yahoo.com logoEdited Transcript of ABMD earnings conference call or presentation 26-Jan-17 1:00pm GMT (NASDAQ:ABMD)
finance.yahoo.com - January 26 at 8:33 PM
seekingalpha.com logoAbiomed -6% on low guidance, Impella disappointment (NASDAQ:ABMD)
seekingalpha.com - January 26 at 3:34 PM
News IconSell-side Consensus Sees ABIOMED, Inc. (NASDAQ:ABMD) Going Where Near-Term? - Aiken Advocate (NASDAQ:ABMD)
aikenadvocate.com - January 26 at 3:29 PM
seekingalpha.com logoABIOMED's (ABMD) CEO Mike Minogue on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:ABMD)
seekingalpha.com - January 26 at 3:29 PM
News IconABIOMED, Inc. (NASDAQ:ABMD) to Post $0.29 Earnings Per Share: Analysts - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 26 at 3:29 PM
sg.finance.yahoo.com logoAbiomed beats 3Q profit forecasts (NASDAQ:ABMD)
sg.finance.yahoo.com - January 26 at 3:29 PM
nasdaq.com logoMedical Product Stocks' Earnings on Jan 26: ABMD, BCR, ABAX - Nasdaq (NASDAQ:ABMD)
www.nasdaq.com - January 25 at 8:20 PM
News IconEarnings in Full Force, Analysts Take Aim at ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 25 at 3:19 PM
News IconVC Score In Focus for ABIOMED, Inc. (NASDAQ:ABMD) - The Tribune (NASDAQ:ABMD)
lakecitytribune.com - January 24 at 1:19 AM
seekingalpha.com logo10 Value Stocks In This Uncertain Trump Market (NASDAQ:ABMD)
seekingalpha.com - January 20 at 3:13 PM
News IconFirms & Funds Reinforcing Their Perception of ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 17 at 8:17 PM
News IconNoteworthy Rating Sentiment Filing: Are Analysts Bearish ABIOMED, Inc. (NASDAQ:ABMD) After Last Week? - Fair View Times (NASDAQ:ABMD)
fairviewtimes.com - January 13 at 3:19 PM
News IconEV Check on Shares of ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 12 at 1:20 AM
News IconWatching Stock Levels for ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 12 at 1:20 AM
News IconABIOMED, Inc. (NASDAQ:ABMD) Could Provide Upside Potentials Between 7 and 15% (NASDAQ:ABMD)
stockmarketdaily.co - January 11 at 3:16 PM
capitalcube.com logoABIOMED, Inc. breached its 50 day moving average in a Bearish Manner : ABMD-US : January 11, 2017 (NASDAQ:ABMD)
www.capitalcube.com - January 11 at 3:16 PM
biz.yahoo.com logoABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ABMD)
biz.yahoo.com - January 10 at 3:24 PM
us.rd.yahoo.com logoAbiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year (NASDAQ:ABMD)
us.rd.yahoo.com - January 10 at 1:37 AM
us.rd.yahoo.com logo4:04 pm Abiomed offers prelim Q3 rev results, reaffirms FY17 outlook ahead of presentation at the Annual J.P. Morgan Healthcare Conference (NASDAQ:ABMD)
us.rd.yahoo.com - January 10 at 1:37 AM
News IconMarket Spotlight: Focusing on Shares of ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 9 at 8:36 PM
rttnews.com logoAbiomed Inc. (ABMD) Is Heading Lower After Preliminary Q3 Report - RTT News (NASDAQ:ABMD)
www.rttnews.com - January 9 at 8:36 PM
feeds.reuters.com logoBRIEF-Abiomed announces 34 pct rise in preliminary Q3 revenue of $114.7 mln (NASDAQ:ABMD)
feeds.reuters.com - January 9 at 4:25 PM
News IconABIOMED’s (ABMD) “Buy” Rating Reiterated at BTIG Research (NASDAQ:ABMD)
forextv.com - January 8 at 3:15 PM
feeds.benzinga.com logoThe MedTech Group: 2017 Top Picks And Catalysts (NASDAQ:ABMD)
feeds.benzinga.com - January 6 at 10:45 AM
nasdaq.com logoNotable Thursday Option Activity: COH, LB, ABMD - Nasdaq (NASDAQ:ABMD)
www.nasdaq.com - January 5 at 3:31 PM
publicnow.com logoAbiomed Third Quarter Fiscal 2017 Earnings and Conference Call Notification (NASDAQ:ABMD)
www.publicnow.com - January 5 at 3:31 PM
News IconWatching the Levels for ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 4 at 8:24 PM
News IconMarket Focus: Zooming in on Shares of ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - January 1 at 3:15 PM
finance.yahoo.com logoAbiomed to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ABMD)
finance.yahoo.com - December 27 at 3:19 PM
News IconCompany in Focus: ABIOMED, Inc. (NASDAQ:ABMD) - Wall Street Beacon (NASDAQ:ABMD)
wsbeacon.com - December 25 at 5:12 AM
nasdaq.com logoInteresting ABMD Put And Call Options For February 2017 (NASDAQ:ABMD)
www.nasdaq.com - December 22 at 1:30 AM


What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

5 brokerages have issued twelve-month price objectives for ABIOMED's shares. Their predictions range from $125.00 to $170.00. On average, they expect ABIOMED's share price to reach $147.00 in the next year.

When will ABIOMED announce their earnings?

ABIOMED is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:

  • According to Zacks Investment Research, "ABIOMED Inc. posted a stellar third quarter of fiscal 2017, beating the Zacks Consensus Estimate on both the counts. Over the past six months ABIOMED has outperformed the broader industry trends in terms of price performance. However, an unfavorable estimate revision trend for the current quarter indicates looming concern ahead of the stock. Intensifying competition in the niche markets is likely to mar the company’s prospects over the long haul. Although Abiomed’s significant international presence helps broaden its customer base, fluctuations in currency exchange rates may impact the company’s international sales. Nevertheless, the flagship Impella product line is a significant growth catalyst for the company." (1/30/2017)

  • Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)

  • Leerink Swann analysts commented, "SGNT reported "messy" Q1 results on soft revs ($68M, -7% vs JEF, -9% vs cons) & one-off expenses related to the SCP divestiture. Mgt reaffirmed FY16 guidance despite these results, but achieving this forecast now relies even more heavily on the co’s expected 5-8 ANDA approvals in 2H16. Elsewhere, mgt discontinued the previously touted iron sucrose program after multiple setbacks but is very focused on executing M&A to bolster the co’s growth profile. Weak Q1 Financials Place a Heavier Onus on New ANDA Approvals to Meet FY16 Guidance: Q1 revs were softer than anticipated ($68M, -7% vs JEF, -9% vs cons) as a weak cough/cold season weighed on anti-infective revs (~$5M impact). In addition, price erosion in the base oncology business & regulatory issues at a key partner also apparently had an impact ($3M+). Despite these dynamics, mgt reaffirmed FY16 guidance as it expects ~$25M of revs to come from current backorders while $20-60M of new sales (5-8 ANDA approvals) are anticipated from the pipeline. In particular, mgt is increasingly confident in its pipeline following a comprehensive review by an independent consultant." (5/5/2016)

Who owns ABIOMED stock?

ABIOMED's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LLC (4.38%), William Blair Investment Management LLC (2.37%), State Street Corp (2.36%), Brown Capital Management LLC (1.62%), Baillie Gifford & Co. (1.35%) and Renaissance Technologies LLC (1.21%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas, Robert Bowen and William J Bolt.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Federated Investors Inc. PA, State Street Corp, Allianz Asset Management AG, Nicholas Investment Partners LP, Thrivent Financial for Lutherans, Guggenheim Capital LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was bought by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Russell Investments Group Ltd., William Blair Investment Management LLC, Columbia Wanger Asset Management LLC, Brown Capital Management LLC, Champlain Investment Partners LLC, Congress Asset Management Co. MA and Fred Alger Management Inc..

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ABIOMED stock cost?

One share of ABIOMED stock can currently be purchased for approximately $116.57.

ABIOMED (NASDAQ:ABMD) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Earnings History Chart

Earnings by Quarter for ABIOMED (NASDAQ:ABMD)

Dividend History Chart

Dividend Payments by Quarter for ABIOMED (NASDAQ:ABMD)

Last Updated on 2/19/2017 by MarketBeat.com Staff